Evidence-Based Cannabis for Dementia-Related Behavioral Agitation
A meta-analysis of 10 RCTs shows medical cannabis can reduce dementia-related agitation—a behavioral symptom that devastates both patients and caregivers. Cannabinoids showed effectiveness comparable to antipsychotics but with a safer profile, especially…
Efficacy and Safety of Cannabinoids for Neuropsychiatric Symptoms of Dementia: A Systematic Review with Meta-analysis.
Neuropsychiatric symptoms (NPS) are highly prevalent in persons with dementia and have been associated with adverse health outcomes. Neuropsychiatric symptom...
Cannabis-Based Spray Shown Feasible and Safe for Alzheimer’s Agitation in UK Care Homes
Despite significant COVID-19 pandemic-related challenges, administering nabiximols through oral mucosa to advanced Alzheimer's patients with agitation demonstrated feasibility and safety. These findings support a larger confirmatory efficacy trial.
Cannabis-Based Spray Shows Early Safety Promise for Alzheimer’s Agitation—But Proof of Efficacy Still Awaited
Despite significant COVID-19 pandemic-related challenges, administering nabiximols through oral mucosa to advanced Alzheimer's dementia patients with agitation demonstrated feasibility and safety. These findings support a larger confirmatory efficacy…
Assessment of clinical factors that predict response to nabilone for agitation in Alzheimer’s disease: A post hoc analysis of a randomized placebo-controlled trial.
Previously, nabilone showed a medium effect size for treating agitation in moderate-to-severe Alzheimer's disease (AD), but response varied. These post hoc a...